Cure8 research brief
This pooled analysis compares multiple microbiota-directed therapies and suggests FMT, probiotics, and synbiotics may improve clinical remission in adults with IBD, with FMT also showing benefit for endoscopic remission. That matters to patients and clinicians evaluating microbiome-based options.
Clinicians, IBD researchers, and adult patients interested in microbiome-directed therapies (FMT, probiotics, synbiotics)
The review identified 40 randomized trials (2,722 patients). Across analyses, FMT, probiotics, and synbiotics were associated with higher odds of clinical remission versus control, with FMT showing the strongest and the only consistent benefit for endoscopic remission.
Prebiotics did not show benefit; antibiotics combined with FMT appeared promising for clinical remission but had wide uncertainty. No treatment class significantly increased adverse events or serious adverse events in the pooled data.
This article is a preprint abstract-level report of a network meta-analysis (structured content depth: abstract), so its methods and results have not undergone full peer review. The authors noted some inconsistency in networks containing FMT, which is important when interpreting comparative rankings.
Preprint/abstract-level report: methods and results have not completed peer review. The authors report inconsistency in some FMT comparisons and uncertainty for some estimates (wide credible intervals), so conclusions about comparative rankings should be cautious.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
The microbiome is increasingly viewed as an influence on IBD development and persistence, and microbiome-directed therapies (like FMT and engineered bacteria) are an active area of research that could one day add to...
